Compare LFUS & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFUS | ARWR |
|---|---|---|
| Founded | 1927 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.2B |
| IPO Year | 1996 | 2009 |
| Metric | LFUS | ARWR |
|---|---|---|
| Price | $404.86 | $85.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $366.67 | $83.40 |
| AVG Volume (30 Days) | 320.1K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 2.96 | N/A |
| Revenue | ★ $757,853,000.00 | $16,142,321.00 |
| Revenue This Year | $14.65 | N/A |
| Revenue Next Year | $6.98 | N/A |
| P/E Ratio | $140.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $227.73 | $15.01 |
| 52 Week High | $500.57 | $95.49 |
| Indicator | LFUS | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 59.26 |
| Support Level | $385.67 | $70.03 |
| Resistance Level | $426.31 | $86.19 |
| Average True Range (ATR) | 14.57 | 4.14 |
| MACD | 0.47 | 0.84 |
| Stochastic Oscillator | 51.72 | 60.82 |
Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.